For decades, a single misleading word shaped how doctors diagnosed and treated one of the most common hormonal conditions in women. On May 12, 2026, polycystic ovary syndrome was officially renamed polyendocrine metabolic ovarian syndrome, or PMOS, after an 11-year global study involving 56 organizations. The PCOS to PMOS shift marks a real turning point in diagnosis and care.
PMOS Changes: Key Takeaways
- Doctors officially renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome on May 12, 2026, after a global study published in The Lancet.
- The PCOS name change fixes a misleading label because pathological ovarian cysts are not actually part of the condition.
- PMOS affects 1 in 8 women, or more than 170 million worldwide, yet up to 70% of them never get diagnosed.
- A three-year transition is underway, with full adoption set for the 2028 update of guidelines used in 195 countries.
What Is Polyendocrine Metabolic Ovarian Syndrome (PMOS)?
Polyendocrine metabolic ovarian syndrome is the new name for the condition once called PCOS, and it is far more than an ovary problem. PMOS is a complex, long-term hormonal disorder that affects weight, metabolic health, mental health, skin, and the reproductive system all at once. About 1 in 8 women live with it, which adds up to more than 170 million worldwide, and studies estimate that 10% to 13% of women of reproductive age have the condition.
The roots of PMOS run deep, tangled up in how the body handles insulin, androgens, and the hormones made by the brain and ovaries. Researchers have also shown that it has polygenic origins, meaning many genes shape how it shows up from one person to the next. That broad, body-wide picture is exactly why the new name leads with hormones instead of cysts.
Why PCOS Was Renamed to PMOS
The old name caused real harm, so experts built a more accurate one.
Problems With the Old “Polycystic” Name
The phrase “polycystic ovary” suggests the condition is all about harmful ovarian cysts, but those cysts simply aren’t a feature of it. A related study by the same experts confirmed there’s no rise in abnormal ovarian cysts at all. By focusing on one organ, the old name shrank a whole-body disorder down to a single misunderstanding, and the cost was steep: missed diagnoses, long delays, and stigma. Many patients felt brushed off whenever their symptoms didn’t match the expected “cysts” picture. None of this is new, either. A US National Institutes of Health workshop flagged the name as inaccurate back in 2012, yet every attempt to fix it stalled for years.
What the New Name Captures
Each word in polyendocrine metabolic ovarian syndrome earns its place. “Polyendocrine” points to the many hormone systems at work, “metabolic” names the effects on weight, blood sugar, and heart health, and “ovarian” covers the follicle and ovulation problems without ever blaming cysts. Experts deliberately dropped “reproductive” because it could deepen stigma in some cultures, and they steered clear of the acronym EMOS, which clashed awkwardly with both “emo” culture and the MERS abbreviation. Keeping PMOS close to the old PCOS was a choice, too. It makes the switch feel like an honest update rather than a brand-new disease.
How the PCOS Name Change Happened
The renaming was the largest effort ever undertaken to rename a medical condition. It took somewhere between 11 and 14 years of global teamwork, led by Professor Helena Teede of Monash University. She worked alongside Professor Terhi Piltonen in Finland, Anuja Dokras in the United States, and Rachel Morman of Verity in the UK, pulling in 56 patient and professional organizations, including the Endocrine Society and ASRM.
What set the process apart was how patient-driven it was. Researchers leaned on surveys, workshops, and even marketing analysis to test every possible option, and more than 22,000 people responded. Patients pushed hardest of all for change. In the end, somewhere between 82% and 86% of respondents wanted an accurate, symptom-based name rather than a generic one or the familiar old acronym.
| Date | Milestone |
|---|---|
| 2012 | NIH workshop flags the PCOS name as inaccurate |
| Sept 2024 | Funding secured |
| Dec 2024 | Governance and engagement set up |
| April–Oct 2025 | First new global survey |
| Nov 2025 | Workshop A with 90 attendees |
| Jan 2026 | Second survey |
| Feb 2026 | Consensus reached on PMOS |
| May 12, 2026 | New name announced in The Lancet |
Symptoms and Health Risks of PMOS
PMOS reaches well beyond the ovaries and touches many parts of the body.
Hormonal and Reproductive Features
- Irregular or missing periods and trouble with ovulation are among the most common signs.
- High androgen levels can trigger extra hair growth, acne, and thinning hair on the scalp.
- Raised anti-Müllerian hormone and disrupted follicle growth often show up on testing.
- Many people struggle to get pregnant and face higher risks during pregnancy.
- Anxiety, depression, and a lower quality of life frequently come along for the ride.
Metabolic and Cardiovascular Risks
Metabolic problems sit right at the core of PMOS. Insulin resistance affects about 85% of people with the condition, and remarkably, roughly 75% of lean individuals have it too. That resistance opens the door to obesity, type 2 diabetes, high blood pressure, high cholesterol, and fatty liver disease. Heart risks climb in step, as the numbers below make clear.
| Condition | Odds Ratio vs. People Without PMOS |
|---|---|
| Composite cardiovascular disease | 1.68 |
| Heart attack | 2.50 |
| Stroke | 1.71 |
What the PCOS to PMOS Change Means for Patients
The change is built to get more people diagnosed and treated the right way. During a managed three-year transition, both PCOS and PMOS will appear side by side, and a large international campaign is busy teaching the new term to patients, doctors, governments, and researchers alike. The name is also being folded into health records and disease classification systems, including ongoing work with the WHO and ICD codes.
Full adoption arrives with the 2028 update of the international guidelines, which already guide care in 195 countries. The goal behind all of it is simple. Earlier diagnosis, better care, and stronger research should finally reach the estimated 70% of people who go undiagnosed today. Patient resources now exist in many languages, so more people can actually understand what’s happening in their own bodies.
Why the PMOS Name Change Matters for Your Health
The switch from PCOS to PMOS does far more than swap a few words. It corrects a name that pushed everyone to fixate on ovarian cysts, and that fixation led straight to missed diagnoses and dismissed symptoms. Now polyendocrine metabolic ovarian syndrome puts hormones and metabolism front and center, where they belong. About 1 in 8 women live with this condition, yet roughly 70% never get diagnosed. The PCOS name change should help close that gap through clearer conversations, better screening, and stronger research, and knowing the new term lets you push for the full care your body truly needs.
Frequently Asked Questions About PMOS
What is polyendocrine metabolic ovarian syndrome (PMOS)? PMOS is the new medical name for the condition long known as PCOS. It’s a hormonal and metabolic disorder that affects many body systems, not just the ovaries.
When did PCOS officially become PMOS? The change became official on May 12, 2026, the day the consensus study appeared in The Lancet.
Why was PCOS renamed? The old name pointed to ovarian cysts, which aren’t really part of the condition. The new name reflects the hormone and metabolic problems that actually drive it.
Did the condition itself change? No. The science and the symptoms stayed exactly the same. Only the name and the way doctors frame it changed.
How many people does PMOS affect? PMOS affects 1 in 8 women, or more than 170 million worldwide, and around 10% to 13% of women of reproductive age have it.
Will doctors still use the term PCOS? Yes, for a while. Both names will appear together throughout the three-year transition so patients and clinicians can adjust.
When will the new name be fully adopted? Full adoption is planned for the 2028 update of the international guidelines, which are used in 195 countries.
Who led the PCOS name change? Professor Helena Teede of Monash University led it, working with experts in Finland, the United States, and the UK, along with 56 organizations.
